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Annexin V is useful in detecting apoptotic cells by binding to phosphatidylserine (PS) that is exposed on the
outer surface of the cell membrane during apoptosis. In this study, we examined the labeling of annexin V-128,
a mutated form of annexin V that has a single cysteine residue at the NH2 terminus, with the thiol-selective
reagent
18F-labeling agent N-[4-[(4-[
18F]ﬂuorobenzylidene)aminooxy]butyl]maleimide ([
18F]FBABM). We also
examined the cell binding afﬁnity of the
18F-labeled annexin V-128 ([
18F]FAN-128). [
18F]FBABM was synthesized
in two-step, one-pot method modiﬁed from literature procedure. (Toyokuni et al., Bioconjugate Chem. 2003, 14,
1253-1259). The average yield of [
18F]FBABM was 23 ( 4% (n ) 4, decay-corrected) and the speciﬁc activity
was ∼6000 Ci/mmol. The total synthesis time was ∼92 min. The critical improvement of this study was identifying
and then developing a puriﬁcation method to remove an impurity N-[4-[(4-dimethylaminobenzylidene)ami-
nooxy]butyl]maleimide 4, whose presence dramatically decreased the yield of protein labeling. Conjugation of
[
18F]FBABM with the thiol-containing annexin V-128 gave [
18F]FAN-128 in 37 ( 9% yield (n ) 4, decay
corrected). Erythrocyte binding assay of [
18F]FAN-128 showed that this modiﬁcation of annexin V-128 did not
compromise its membrane binding afﬁnity. Thus, an in ViVo investigation of [
18F]FAN-128 as an apoptosis imaging
agent is warranted.
INTRODUCTION
Apoptosis, or programmed cell death, is an essential com-
ponent for embryogenesis and homeostasis. Dysregulation of
apoptosis is associated with many diseases such as cancer,
autoimmunity, and neurodegenerative disorders (1). Many
anticancer therapies exert their therapeutic effects by inducing
apoptosis in tumor cells. A suitable in ViVo marker for
noninvasive imaging of apoptosis would be useful for both
clinical care and drug development.
One of the early characteristics of apoptosis is the external-
ization of phosphatidylserine (PS) molecules on cell membranes,
which promotes recognition and phagocytic removal (2, 3). In
culture, once apoptosis is triggered, the PS externalization begins
to occur within one hour (2). Annexin V, a 36 kDa endogenous
cytoplasmic protein, binds with high afﬁnity (Kd ∼10 nM) to
membrane-bound PS in a Ca
2+-dependent manner (4). Annexin
V staining has been a standard practice for the assessment of
apoptosis in Vitro for the past decade. More recently, radiola-
beled annexin V has been actively investigated to image cell
death (5–8).
99mTc-labeled annexin V showed promising results
in early clinical SPECT studies (9–11), but its low sensitivity
has limited its broader application. To take advantage of the
higher resolution and more accurate quantiﬁcation of PET,
labeling annexin V with short half-life positron-emitters such
as
18F is of particular interest.
We (12) and others (13, 14) have reported the labeling of
wild-type annexin V with N-succinimidyl-4-
18F-ﬂuorobenzoate
([
18F]SFB). We have also demonstrated that the
18F-labeled
annexin V ([
18F]ﬂuoroannexin or [
18F]FAN) showed increased
uptake in rat liver proportional to apoptosis after apoptosis was
chemically induced (15). The rapid blood clearance and urinary
excretion of [
18F]FAN suggest its potential as a PET imaging
agent. This radiotracer, however, has its own disadvantages. The
predominant renal clearance increases the radiation burden to
the kidneys and bladder, and a patient would have to be
catheterized if the diagnostic area of interest were in the
abdomen (15). Moreover, this labeling method for annexin V
is nonspeciﬁc, as the reaction is between the prosthetic group
([
18F]SFB) and any available NH2 groups in this protein. There
are at least 23 potential sites for this reaction to occur in each
annexin V molecule, some near the active binding site of the
protein. A recent report conﬁrms that amine-directed chemical
modiﬁcation of annexin V reduces its membrane-binding activity
even at low stoichiometries (16). Multiple substitutions of
annexin V with [
18F]SFB could mean disproportional signaling
by low-afﬁnity molecules in PET imaging. Therefore, a site-
speciﬁc method to label annexin V with only one substitution
per molecule should have an advantage over the [
18F]SFB-
modiﬁed version.
An alternative strategy to label proteins involves targeting
the free thiol groups that are present only in cysteine residues.
Thiol reactive agents such as N-substituted maleimides and
iodoacetamide can be used to modify proteins at cysteines at
speciﬁc sites (17–20). Annexin V-128 is a mutated form of
annexin V containing only one cysteine. The initiator Met at
position one is deleted and a six amino acid extension containing
one cysteine is added at the N-terminus. The N-terminus does
not play a role in the binding activity of annexin V and so this
modiﬁcation does not change the binding afﬁnity of annexin
V-128 for PS. Site-speciﬁc labeled (with
99mTc) annexin V-128
derivatives showed twice as much in ViVo apoptosis-speciﬁc
uptake in rat liver models as did amine-derivatized forms of
annexin V (16). A previous approach to label thiol-containing
molecules with N-[4-[(4-[
18F]ﬂuorobenzylidene)aminooxy]bu-
tyl]maleimide ([
18F]FBABM) used a two-step/two-pot synthesis
that was labor intensive and gave low yield with larger
biomolecules such as 5′ -S-ODN (21). In this paper, we report
an improved synthesis and efﬁcient puriﬁcation of [
18F]FBABM,
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18F]annexin V-128 ([
18F]FAN-128) with
this thiol-reactive reagent. The PS binding afﬁnity of [
18F]FAN-
128 and its potential as a PET imaging agent for cell death are
also discussed.
MATERIALS AND METHODS
General. All reagents and solvents were purchased from
Aldrich Chemical Co. (Milwaukee, WI) as reagent grade and
were used without puriﬁcation unless otherwise noted. The
labeling precursor, 4-trimethylammoniumbenzaldehyde triﬂate
1, was prepared as described by Haka et al. (24) and stored in
a sealed vial over desiccant in the refrigerator. The coupling
precursor, N-[4-(aminooxy)butyl]maleimide 3, as a HCl salt was
synthesized according to Toyokuni et al. (21) with modiﬁcations
and stored over desiccant in the refrigerator. Enriched (97%)
[
18O]water was obtained from Medical Isotopes, Inc. (Pelham,
NH). Chromaﬁx 30-PS-HCO3
18F separation cartridges were
obtained from GE Medical Systems and C-18 SepPak (light)
cartridges were obtained from Waters Corp. (Milford, MA). The
ﬁrst part of the radiosynthesis (the production of the radiopre-
cursor [
18F]FBABM) was performed using a GE Tracerlab FXFN
automatic synthesis module. The second part of the radiosyn-
thesis (the radio-labeling of annexin V-128) was done manually
outside the GE box.
1H NMR data were obtained with a Varian
300 MHz NMR instrument. Quality control of the puriﬁed
radioactive product was performed on a Waters 2690 HPLC
module coupled with an in-line Micromass ZMD mass
spectrometer.
Preparation of Annexin V-128. Annexin V-128 (∼2 mg/
mL in 20 mM HEPES sodium, 100 mM NaCl, pH 7.4) was
prepared and puriﬁed as described (26). The protein was reduced
with 1 mM dithiothreitol (DTT) for 15 min at 37 °C and then
applied to a Sephadex G-25 column equilibrated with deoxy-
genated buffer (20 mM HEPES-sodium, 100 mM NaCl, pH 7.4)
to remove the reductant. Protein concentration was measured
by absorbance at 280 nm and the reduced protein was used for
labeling within 6 h.
Synthesis of N-[4-[(4-Dimethylaminobenzylidene)ami-
nooxy]butyl]maleimide 4. A solution of 4-dimethylaminoben-
zaldehyde (17 mg, 0.1 mmol) and 3·HCl (20 mg, 0.09 mmol)
in anhydrous DMF (1 mL) was stirred at r.t. for 16 h. The
reaction mixture was then poured into water and extracted with
diethyl ether. After drying over anhydrous Na2SO4, the ether
solution was decanted, concentrated under reduced pressure, and
then loaded onto a silica TLC plate (Alltech Silica Gel 60 F254
5 × 20 cm). The TLC plate was developed with 40% diethyl
ether in hexanes (v:v) and the product (Rf ∼ 0.34) was washed
off with ether as a yellowish solid (14 mg, 0.05 mmol, 50%).
mp 51 °C.
1H NMR (CDCl3, 300 MHz) δ 1.65-1.75 (m, 4H),
2.99 (s, 6H), 3.57 (t, J ) 6.0 Hz, 2H), 4.12 (t, J ) 6.0 Hz, 2H),
6.66 (d, J ) 9.0 Hz, 2H), 6.67 (s, 2H), 7.43 (d, J ) 9.0 Hz),
7.97 (s, 1H). MS (ESI+): 316 [M+H]
+ HRMS (ESI+):
[M+Na]
+ Calc. 338.1475; Found: 338.1481.
Synthesis of FBABM. A solution of 4-ﬂuorobenzaldehyde
(31 µL, 0.29 mmol) and 3•HCl (41 mg, 0.18 mmol) in DMF (2
mL) was stirred at r.t. for 30 min. The reaction mixture was
then poured into water and extracted with diethyl ether. After
drying over anhydrous Na2SO4, the ether solution was decanted
and concentrated under reduced pressure, and then loaded onto
a silica ﬂash chromatography column and eluted with 40%
diethyl ether in hexanes (v:v) to give FBABM (50 mg, 0.17
mmol, 91%) as a white solid. mp 81 °C.(Lit. (21)7 9 -81 °C)
1H NMR (CD3OD, 300 MHz) δ 1.55-1.70 (m, 4H), 3.49 (t, J
) 6.0 Hz, 2H), 4.09 (t, J ) 6.0 Hz, 2H), 6.74 (s, 2H), 7.07 (dd,
J ) 9.0 Hz, 9.0 Hz, 2H), 7.57 (dd, J ) 9.0 Hz, 6.0 Hz, 2H),
8.03 (s, 1H). MS (ESI+): 291 [M+H]
+.
Radiosynthesis of [
18F]FBABM. Cyclotron-produced [
18F]ﬂu-
oride in H2
18O was forced through a Chromaﬁx
18F separation
cartridge with helium pressure using a GE Tracerlab FXFN
automated synthesis unit. The concentrated
18F
- on the cartridge
was then eluted with 1.4 mg K2CO3 in 0.5 mL 1:1 (v:v)
acetonitrile/water solution into the reaction vessel of the FXFN
box. A solution of 7.5 mg Kryptoﬁx[2,2,2] in 2 mL anhydrous
acetonitrile was then added to the same reaction vessel and the
whole mixture was azeotropically evaporated to dryness under
heat and reduced pressure. A solution of 4-5 mg 4-trimethy-
lammoniumbenzaldehyde triﬂate 1 in 1 mL anhydrous aceto-
nitrile was then pushed into the reactor, pressurized (∼200
mbar), and heated at 100 °C. After 15 min, the reaction vessel
was cooled to r.t. before 8-9m g3 in 1.5 mL methanol was
added. After stirring at r.t. for 15 min, the mixture was slowly
evaporated to <0.5 mL with heat (50 °C) under vacuum. After
cooling to r.t., 1.5 mL of 45% ethanol in water (v:v) was added
to the reaction vessel and the whole mixture was transferred to
the HPLC loop. Semipreparative HPLC was performed with a
C18 column (Phenomenex Prodigy ODS(3), 5 µm, 250 × 10
mm) eluted with 45% ethanol/water (v:v) at 3 mL/min and 50
°C. The chemically and radiochemically (>99%) pure fraction
containing [
18F]FBABM was collected (∼12 mL; tR ∼ 38-40
min). The chemical and radiochemical purity was assessed with
a C18 analytical HPLC column (Phenomenex Inertisil ODS-3,
100 × 2.1 mm, 5 µm, eluted with 55% methanol/water (v:v) at
0.3 mL/min ﬂow rate and 40 °C with in-line mass detection.
Labeling of Annexin V-128 with [
18F]FBABM. Puriﬁed
[
18F]FBABM from the previous step (∼12 mL) was diluted with
water (∼50 mL) and passed through a Waters C18 SepPak that
had been preconditioned with 5 mL ethanol and 5 mL water.
The SepPak was washed with additional 10 mL water and the
excess water was expelled with a push of air. 2 mL of ether
was then pushed through the SepPak to elute the product into
a clean 5 mL glass test tube. The ether phase of the biphase
mixture was drawn out and transferred into a clean 5 mL BD
Vacutainer test tube. The ether was then removed by evaporation
under a gentle ﬂow of argon at 50 °C. After cooling to r.t.,
approximately 0.7 mg freshly prepared annexin V-128 in 0.5
mL buffer (20 mM HEPES, 100 mM NaCl, pH 7.4) was
carefully added to the residual ﬁlm and incubated for 15 min
with periodic gentle agitation. Labeled [
18F]ﬂuoroannexin V-128
([
18F]FAN-128) was isolated by a semipreparative size-exclusion
column (BioSep SEC-S 2000, 300 × 7.8 mm) eluted at 1 mL/
min with 10 mM phosphate/150 mM NaCl (pH ) 7). [
18F]FAN-
128 was the ﬁrst radioactive peak eluted from the column with
a retention time of ∼7-9 min.
Cell-Binding Assay of [
18F]FAN-128. The membrane bind-
ing afﬁnity of [
18F]FAN-128 was determined following the
procedure described by Tait et al. (22, 16) Brieﬂy, mixtures of
red blood cells (RBCs) with exposed PS on the outer surface
of the cell membrane (Coulter “4C Plus” Cell Control, Fullerton,
CA), [
18F]FAN-128 (diluted to a ﬁnal concentration of 1 nM)
in buffer (100 mM NaCl, 50 mM Hepes-Na, pH 7.4, 0.02%
NaN3, 1 mg/ml BSA) and CaCl2 at precise concentrations
(between 0 and 3 mM) were prepared. The mixtures were
incubated for 10 min. at r.t. After centrifugation, the supernatant
was discarded. Then the RBCs with bound [
18F]FAN-128 were
washed with the same buffer containing CaCl2 at the same
concentrations and recentrifuged and the supernatant was
discarded. Membrane-bound [
18F]FAN-128 was then released
with assay buffer containing 5 mM EDTA and counted in the
gamma counter.
RESULT AND DISCUSSION
Chemistry. Our synthesis of [
18F]FBABM builds on the
approach reported by Toyokuni et al. (21) (Scheme 1). Brieﬂy,
triﬂate 1 was heated with dried [
18F]KF in anhydrous acetonitrile
in the presence of Kryptoﬁx[2,2,2] to generate [
18F]FBA 2,
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puriﬁcation by HPLC. Their two-step/two-pot synthesis of
[
18F]FBABM was used to label the thiol-containing tripeptide
glutathione (GSH) and a 5′ -thiol-functionalized oligodeoxy-
nucleotide (5′ -S-ODN). This synthesis started with the genera-
tion of 2 followed by a C18 SepPak puriﬁcation. After coupling
to the heterobifunctional linker N-[4-(aminoxy)butyl]maleimide
3 using the oxime O-ether formation reaction and HPLC
puriﬁcation, [
18F]FBABM was formulated in acetonitrile and
successfully labeled GSH or 5′ -S-ODN. This method, however,
has disadvantages for routine protein labeling. First, the synthesis
of [
18F]FBABM was labor-intensive, with a two-pot setup and
a C18 SepPak puriﬁcation step in between. Second, although
the labeling of GSH gave good yield (70% decay corrected),
the yield in labeling larger biomolecules such as 5′ -S-ODN (5%
decay corrected) was low. The concentrations of the GSH or
the 5′ -S-ODN in these reactions were 6 mM and 0.1 mM,
respectively. The radiochemical yield of radiolabeled peptides/
proteins or other biomolecules via prosthetic groups typically
decreases as the concentration of the biomolecule decreases.
For an even larger molecule such as annexin V-128, which is
usually obtained in ∼30 µM concentration, the radiochemical
yield might be even lower than 5%. Indeed, our initial attempts
to label annexin V-128 with [
18F]FBABM synthesized by
closely following the literature procedure (12) gave no yield.
In addition to the slow rate of reaction associated with dilute
conditions, the presence of nonradioactive maleimide-containing
impurities, which would compete with [
18F]FBABM for the
available thiol groups, could be an important factor that results
in the dramatic decrease in yield. In the Toyokuni report, there
was little information on the chemical purity of the [
18F]FBABM
produced. We focused our investigation on simpliﬁcation of the
radiosynthesis and puriﬁcation of the [
18F]FBABM.
We found that the C18 SepPak puriﬁcation was not required
for [
18F]FBABM synthesis; the two-step reactions proceed
smoothly in one pot. Starting with ∼850 mCi [
18F]ﬂuoride, 110
( 14 mCi (n ) 4) of puriﬁed [
18F]FBABM was obtained in
∼92 min (23 ( 4% decay corrected radiochemical yield) with
>99% radiochemical purity and a speciﬁc activity of ∼6000
Ci/mmol. This yield is comparable to that from the two-pot
procedure (21), but with a process that can be automated.
Although theoretically, [
18F]FBABM could be formed as both
E- and Z-isomers, we observed only one isomer (tentatively
assigned to possess the E-conﬁguration) (21) under our reaction
condition. This was conﬁrmed by coeluting with the cold
standard of FBABM, whose NMR spectrum revealed only one
isomer, on HPLC. During the preparation of this manuscript,
Berndt et al. reported a one-pot method to prepare a similar
thiol-reactive labeling agent N-[6-(4-[
18F]ﬂuorobenzylidene)-
aminooxyhexyl]maleimide ([
18F]FBAM) with similar yield to
ours (23). Their method, however, includes an extra prepuriﬁ-
cation step using solid-phase extraction on LiChrolut RP18
cartridge before semipreparative HPLC puriﬁcation.
The synthesis of [
18F]FBA 2 from the triﬂate precursor 1 was
traditionally carried out by heating the dried [
18F]KF/Krypto-
ﬁx[2,2,2] in a high-boiling polar aprotic solvent such as
DMSO (24, 25). We chose the lower boiling acetonitrile because
it could be easily removed by evaporation. Compared with
DMSO, the use of acetonitrile did not compromise the yield of
[
18F]FBA (Table 1). Similar yields were obtained while the same
amounts of precursors were used. A smaller amount of precur-
sors resulted in decreased yields of 2. Using 4 mg triﬂate
precursor struck a balance between reasonably high yield and
acceptably lower quantity of material introduced into the system.
Compared to the Toyokuni report (21), the yield of the coupling
reaction dropped from ∼70% to ∼40% (calculated from the
yield of the ﬁrst step and the overall yield), but the advantage
of easier production of this radiotracer outweighed this reduction
of yield. It is important to note that, because FBA is a volatile
compound at elevated temperature, it is crucial to cool the
reaction mixture to r.t. before opening the reaction vessel to
add the coupling precursor.
The critical factor for optimal protein labeling with [
18F]F-
BABM is the chemical purity of the product. We suspected that
a maleimide side product was present that would compete with
[
18F]FBABM for reaction with thiol groups. HPLC-MS was
used to identify this major contaminant as N-[4-[(4-dimethy-
laminobenzylidene)aminooxy]butyl]maleimide (4) (estimated
>100 µg from a typical run described above) derived from the
4-dimethylaminobenzaldehyde formed inevitably during the
initial nucleophilic ﬂuorination step (Scheme 2). In a typical
run, about 300 µg 4-dimethylaminobenzaldehyde was detected
after this ﬁrst step. The identity and quantity was determined
by HPLC-MS analysis, in comparison to an authentic sample.
Our initial attempt to label annexin V-128 with [
18F]FBABM
containing 4 gave no yield, presumably due to a competition for
the single thiol group by the vast molar excess of the alternative
maleimide contaminant 4. In a typical labeling reaction, the molar
ratio of FBABM to annexin V-128 (generally 0.6 mg was used)
Scheme 1. Synthesis of [
18F]FBABM
Table 1. Yield of FBA (2) under Different Reaction Conditions
a
solvent amt. of precursor 1 (mg) temperature (°C) yield (%)
c
DMSO 8 100 90
THF 4 80
b 0
CH3CN 2 100
b 10
CH3CN 3 100
b 20
CH3CN 4 100
b 75
CH3CN 8 100
b 90
a All reactions were carried out by heating the precursor in 1 mL
solvent for 15 min in a closed reaction vessel in a GE Tracerlab FXFN
automated synthesis module.
b Heated under helium pressure (200
mbar).
c Determined from radio-HPLC chromatograms of the crude
product. Data represent an average of 3 runs.
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Attempts to remove the undesired 4-dimethylaminobenzaldehyde
after the ﬁrst step with a C18 SepPak were unsuccessful. The
removal of 4 from the ﬁnal product [
18F]FBABM proved to
be challenging. The calculated log P values for FBABM and 4
are 1.91 and 1.85, respectively (Molinspiration program: http://
www.molinspiration.com/cgi-bin/properties). The two compounds
coeluted using the HPLC method from the literature (21). We
developed a useful separation by using Phenomenex Prodigy
ODS(3) 5 µm 250 × 10 mm column. At 50 °C and 45% ethanol/
water as the eluent at 3 mL/min, 4 was completely removed from
[
18F]FBABM (impurity tR(4)∼26-28 min, tR(FBABM) ∼34-38
min). A typical semipreparative HPLC chromatogram is shown in
Figure 1. No detectable amount of 4 was present in the puriﬁed
[
18F]FBABM product. We realize that, in this isocratic HPLC
method, although a complete separation of impurity 4was achieved,
the long retention time of the [
18F]FBABM is disadvantageous for
routine production. We are currently investigating alternative
puriﬁcation method with gradient HPLC.
Annexin V-128 (26) contains one cysteine in its N-terminus.
The single naturally occurring cysteine residue in its interior
domain has been mutated to a serine in order to eliminate the
possibility of modiﬁcation by thiol-reactive prosthetic conjugat-
ing agents. Annexin V-128 is freshly reduced immediately prior
to each labeling study with DTT to ensure that the free thiol is
fully accessible. The protein is puriﬁed of excess DTT by eluting
through a Sephadex column.
The puriﬁed [
18F]FBABM was concentrated onto a C18 SepPak,
washed off with diethyl ether, and taken to dryness. After
evaporation, the [
18F]FBABM was incubated with annexin V-128
in HEPES buffer (pH ) 7.4, 0.5 mL). It is noted that the number
of liquid transfers and the contact surface area with the reaction
vessel should be minimized to reduce unnecessary loss of annexin
V-128 due to surface adsorption of the protein. Even using a careful
transfer technique, approximately 1/3 of the total radioactivity is
typically lost in transfers for injection onto the size-exclusion
column (SEC). After HPLC puriﬁcation, radiochemically pure
(>98%) [
18F]FAN-128 was obtained with 37 ( 9% yield (n ) 4,
decay-corrected) from [
18F]FBABM. The total recovery of radio-
activity from the SEC was >90% with the radioactive peak at 7-9
min being [
18F]FAN-128. The unreacted [
18F]FBABM was
retained for >1 h on the SEC column.
As a negative control, we repeated the reaction under the
same condition using wild-type annexin V instead of mutated
annexin V-128. Wild-type annexin V has one internal cysteine
but it does not have a free thiol group on its N-terminus. In
this reaction, the yield of
18F-labeled protein was negligible
(<0.2%). This result shows that, under our reaction conditions,
[
18F]FBABM does not react with other nucleophiles such as
the free NH2 groups in annexin V, and the single cysteine
residue that is present in the interior domain of wild-type
annexin V is not readily accessible for maleimide binding.
Therefore, we are able to conclude that the [
18F]FBABM
labeling of annexin V-128 is site-speciﬁc. The mutation of Cys-
316 to Ser in annexin V-128 may not be necessary for future
annexin V based tracer design.
[
18F]FAN-128 PS Binding Assay. The in Vitro membrane-
binding afﬁnity of [
18F]FAN-128 was determined by erythrocyte
binding using the method reported by Tait et al. (16) The
commercially available RBCs had exposed PS on their outer
surfaces of the cell membranes because of the preservatives used
(27). Annexin binding to PS is calcium dependent. By titrating
calcium instead of protein, this method allows an accurate
measurement of annexin binding at <1% occupancy, a value
similar to that for in ViVo imaging where the membrane is far
from saturated with protein. A typical binding curve for
[
18F]FAN-128 is presented in Figure 2. The binding afﬁnity was
measured by determining EC50 and slope from this experimental
titration curve (22). The negative log of the binding constant,
pK, is equal to -(n log10EC50 + log10[membrane]), where n is
the number of Ca
2+ ions interacting with each annexin V
molecule, the EC50 is the molarity of Ca
2+ at which cell binding
is half of the maximal value, and [membrane] is the concentra-
tion of annexin V-binding sites in the assay (16). Seven batches
of [
18F]FAN-128 gave an average pK of 28.5 ( 1.8, an EC50
of approximately 1 mM, and a slope (Hill coefﬁcient) between
7 and 8. This compares favorably with reported values for wild-
type annexin V of a pK around 30, EC50 close to 1, and a slope
o f8( 26, 16). These data indicate that the in Vitro binding activity
Scheme 2. Formation of 4
Figure 1. A typical semipreparative HPLC chromatogram for [
18F]F-
BABM puriﬁcation. (Phenomenex Prodigy ODS-3, 250 × 10 mm, 5
µm, eluted with 45% ethanol/water v:v at 3 mL/min and 50 °C).
Figure 2. Typical binding curve of [
18F]FAN-128 to PS-enriched
membranes. Typical binding curve of [
18F]FAN-128 as a factor of
calcium concentration. [
18F]FAN-128 is held constant well below its
Kd (at 1 nM), while calcium is titrated between 0 and 3 mM (maximal
binding is observed at 2-2.5 mM Ca
2+). The membrane-bound
radioactivity is plotted versus the concentration of Ca
2+ present. pK
value is calculated from slope (N) and midpoint of titration curve (EC50)
(16). Two measurements are done for each data point.
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cantly different from that of the wild-type and an in ViVo
investigation of [
18F]FAN-128 as an apoptosis imaging agent
is warranted.
CONCLUSION
We have developed an improved, one-pot synthesis of the thiol-
reactive labeling reagent [
18F]FBABM. It gives satisfactory radio-
chemical yield and can be automated for routine production. The
critical improvement was identifying and then developing a
puriﬁcation method to remove the impurity N-[4-[(4-dimethylami-
nobenzylidene)aminooxy]butyl]maleimide (4). The presence of this
impurity in [
18F]FBABM was dramatically decreasing the yield
of labeled protein by competing for the available thiol groups. To
our knowledge, this is the ﬁrst time that this important issue has
been addressed. We have also achieved an efﬁcient synthesis of
18F-labeled annexin V-128 ([
18F]FAN-128), a 36 kDa protein
containing a single thiol group, with the [
18F]FBABM radiopre-
cursor. This maleimide modiﬁcation of annexin V-128 does not
compromise its membrane binding afﬁnity.
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